Molecular Nutrition

Fibroblast Growth Factor-23:Functions in Bone Mineral Metabolism and Regulation Mechanism

Expand
  • 1. College of Veterinary and Animal Science, Shenyang Agricultural University, Shenyang 110866, China;
    2. Shenyang 204 Hospital, Shenyang 110043, China

Received date: 2017-03-12

  Online published: 2017-09-28

Abstract

fibroblast growth factor-23 (FGF23) as a bone-derived hormone plays an important role in bone mineral metabolism by mediating the negative feedback loops formed by parathyroid gland, kidney, bone and vitamin D to constructing a bone-kidney-parathyroid gland endocrine axis. The secretion, activity and intracellular processes of FGF23 are regulated by calcium, phosphate, iron, vitamin D, parathyroid hormone (PTH), fibroblast growth factor receptor (FGFR)/FGF and posttranslational modifications. With the increase of study on FGF23, the researchers have explored new therapeutic interventions on bone mineral metabolism disorder. In order to provide reference for relevant research, functions and regulation mechanism of FGF23 in bone mineral metabolism were reviewed in this paper.

Cite this article

DONG Zhongliang, REN Xiaoman, BU Shuyang, SHAN Aiting, WANG Yuting, YANG Jiancheng . Fibroblast Growth Factor-23:Functions in Bone Mineral Metabolism and Regulation Mechanism[J]. Chinese Journal of Animal Nutrition, 2017 , 29(10) : 3467 -3471 . DOI: 10.3969/j.issn.1006-267x.2017.10.006

References

[1] SUGIMOTO H,SHINKYO R,HAYASHI K,et al.Crystal structure of CYP105A1(P450SU-1) in complex with 1α,25-dihydroxyvitamin D3[J].Biochemistry,2008,47(13):4017-4027.  

[2] TOXQUI L,VAQUERO M P.Chronic iron deficiency as an emerging risk factor for osteoporosis:a hypothesis[J].Nutrients,2015,7(4):2324-2344.  

[3] ITO M,SAKAI Y,FURUMOTO M,et al.Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells[J].American Journal of Physiology-Endocrinology and Metabolism,2005,288(6):E1101-E1109.

[4] MEIR T,DURLACHER K,PAN Z,et al.Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription[J].Kidney International,2014,86(6):1106-1115.  

[5] LAVI-MOSHAYOFF V,WASSERMAN G,MEIR T,et al.PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure:a bone parathyroid feedback loop[J].American Journal of Physiology.Renal Physiology,2010,299(4):F882-F889.

[6] BACIC D,LEHIR M,BIBER J,et al.The renal Na+/phosphate cotransporter NaPi-Ⅱa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone[J].Kidney International,2006,69(3):495-503.  

[7] SHIMADA T,HASEGAWA H,YAMAZAKI Y,et al.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis[J].Journal of Bone and Mineral Research,2004,19(3):429-435.

[8] SHIMADA T,MIZUTANI S,MUTO T,et al.Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia[J].Proceedings of the National Academy of Sciences of the United States of America,2001,98(11):6500-6505.  

[9] DAVID V,DAI B,MARTIN A,et al.Calcium regulates FGF-23 expression in bone[J].Endocrinology,2013,154(12):4469-4482.  

[10] RODRIGUEZ-ORTIZ M E,LOPEZ I,MUÑOZ-CASTAÑEDA J R,et al.Calcium deficiency reduces circulating levels of FGF23[J].Journal of the American Society of Nephrology,2012,23(7):1190-1197.  

[11] ECONS M J,MCENERY P T.Autosomal dominant hypophosphatemic rickets/osteomalacia:clinical characterization of a novel renal phosphate-wasting disorder[J].The Journal of Clinical Endocrinology & Metabolism,1997,82(2):674-681.  

[12] IMEL E A,PEACOCK M,GRAY A K,et al.Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans[J].The Journal of Clinical Endocrinology & Metabolism,2011,96(11):3541-3549.  

[13] IMEL E A,GRAY A K,PADGETT L R,et al.Iron and fibroblast growth factor 23 in X-linked hypophosphatemia[J].Bone,2014,60:87-92.

[14] XIAO Z S,HUANG J S,CAO L,et al.Osteocyte-specific deletion of Fgfr1 suppresses FGF23[J].PLoS One,2014,9(8):e104154.

[15] WU A L,FENG B,CHEN M Z,et al.Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia[J].PLoS One,2013,8(2):e57322.

[16] XIAO L P,ESLIGER A,HURLEY M M.Nuclear fibroblast growth factor 2(FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro[J].Journal of Bone and Mineral Research,2013,28(1):35-45.  

[17] HOMER-BOUTHIETTE C,DOETSCHMAN T,XIAO L P,et al.Knockout of nuclear high molecular weight FGF2 isoforms in mice modulates bone and phosphate homeostasis[J].Journal of Biological Chemistry,2014,289(52):36303-36314.  

[18] BERGWITZ C,BANERJEE S,ABU-ZAHRA H,et al.Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis[J].The Journal of Clinical Endocrinology & Metabolism,2009,94(11):4267-4274.  

[19] KATO K,JEANNEAU C,TARP M A,et al.Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis.Secretion of fibroblast growth factor 23 requires O-glycosylation[J].The Journal of Biological Chemistry,2006,281(27):18370-18377.  

[20] TAGLIABRACCI V S,ENGEL J L,WILEY S E,et al.Dynamic regulation of FGF23 by Fam20C phosphorylation,GalNAc-T3 glycosylation,and furin proteolysis[J].Proceedings of the National Academy of Sciences of the United States of America,2014,111(15):5520-5525.  

[21] CUI J X,XIAO J Y,TAGLIABRACCI V S,et al.A secretory kinase complex regulates extracellular protein phosphorylation[J].Elife,2015,4:e06120.

[22] RYAN E A,REISS E.Oncogenous osteomalacia.Review of the world literature of 42 cases and report of two new cases[J].American Journal of Medicine,1984,77(3):501-512.  

[23] CARPENTER T O,IMEL E A,RUPPE M D,et al.Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia[J].Journal of Clinical Investigation,2014,124(4):1587-1597.  

[24] IMEL E A,ZHANG X P,RUPPE M D,et al.Prolonged correction of serum phosphorus in adults with x-linked hypophosphatemia using monthly doses of KRN23[J].The Journal of Clinical Endocrinology & Metabolism,2015,100(7):2565-2573.  

[25] KAPELARI K,KÖHLE J,KOTZOT D,et al.Iron supplementation associated with loss of phenotype in autosomal dominant hypophosphatemic rickets[J].The Journal of Clinical Endocrinology & Metabolism,2015,100(9):3388-3392.  
Outlines

/